Actinomycin D

Experimental studies with actinomycin D.

Actinomycin D has been tested on mouse tu mors, with varying degrees of success, as an anti-neoplastic agent. Dramatic inhibition of some ascites (mouse) tumors has been reported by Sugiura (14) and Gregory et al. (6). Reilly (11) and Sugiura (14) are in agreement that actino-mycin D has slight antineoplastic activity against S-180, and Farber (3) demonstrated antitumor activity against the mal...

Suppression of erythropoiesis by actinomycin D. I. Evolutional change of hemopoiesis by actinomycin D.

For the purpose of revealing whether the sensitivity of the erythropoiesis to actinomycin D (AMD) differs among different animal species, and to see the acting site of AMD on erythroid cell specialization stage, the author observed the hourly change of the blood cell counts and bone marrow cells after AMD administration to mice, rats and rabbits, and obtained the following results: 1. The data ...

AKT mediates actinomycin D-induced p53 expression

At high cytotoxic concentrations, actinomycin D (ActD) blocks transcription, decreasing levels of MDM2 and thus causing p53 stabilization. At low cytostatic concentrations, ActD causes ribosomal stress, which decreases MDM2 activity, resulting in p53 stabilization and activation. ActD can thus be used for p53-based cyclotherapy. We analyzed pathways mediating ActD-induced p53 expression. Inhibi...

Laser microdissection of actinomycin D segregated nucleoli.

Inhibition of Mycoplasma pneumoniae by actinomycin D.

Growth of Mycoplasma pneumoniae was completely prevented by 0.06 mug of actinomycin D/ml, and 0.00375 mug/ml caused 90% inhibition. It thus appears that M. pneumoniae is more susceptible to actinomycin D than previously reported. Low concentrations (0.019 mug/ml) of the antibiotic primarily inhibited ribonucleic acid synthesis and high concentrations (20 mug/ml) inhibited both ribonucleic and d...